Progynova, 2 mg tablets 21 pcs

Progynova contains estrogen – estradiol valerate, which is converted in the human body into natural 17β-estradiol. Taking Progynova does not suppress ovulation, and there is virtually no change in the production of hormones in the body itself.

Estradiol replenishes estrogen deficiency in the female body after menopause and provides effective treatment of psycho-emotional and vegetative menopausal symptoms (such as hot flashes, increased sweating, sleep disorders, increased nervous excitability, irritability, palpitations, cardialgia, dizziness, headache, decreased libido, muscle and joint pain); involution of skin and mucous membranes, especially mucous membranes of the genitourinary system (urinary incontinence, dryness and irritation of the vaginal mucosa, painfulness during sexual intercourse).

MWH with an adequate dose of estrogen, such as occurs with Progynova reduces bone resorption and delays or stops bone loss in postmenopause. Long-term use of hormone replacement therapy (HRT) has been shown to reduce the risk of periprosthetic bone fractures in postmenopausal women. The rate of bone mass decline when MHT is withdrawn is comparable to that seen in the immediate postmenopausal period. It has not been shown that using MHT can restore bone mass to premenopausal levels.

MGT also has beneficial effects on the collagen content of the skin, as well as skin density, and can also slow the formation of wrinkles.

MGT lowers total cholesterol, low-density lipoprotein cholesterol (LDL), and raises high-density lipoprotein cholesterol (HDL) and triglycerides. The addition of gestagen can interfere to some extent with the effects of estradiol on metabolism. In general, the metabolic effects of MHT are seen as positive and are thought to be involved in reducing the risk of cardiovascular disease in postmenopausal women.

Women who have not had their uterus removed are advised to take additional gestagen for at least 10 days each cycle when using Progynova. This reduces the risk of endometrial hyperplasia and the associated risk of adenocarcinoma in women in this group.

Indications

Hormone replacement therapy (HRT) for menopausal disorders, involutive changes in the skin and genitourinary tract, depressive states during menopause, as well as symptoms of estrogen deficiency due to natural menopause or sterilization;

prevention of postmenopausal osteoporosis.

Pharmacological effect

Proginova contains estrogen – estradiol valerate, which in the human body is converted into natural 17β-estradiol. While taking Proginova, ovulation is not suppressed, and the production of hormones in the body itself remains virtually unchanged.

Estradiol replenishes the deficiency of estrogen in the female body after menopause and provides effective treatment of psycho-emotional and autonomic menopausal symptoms (such as hot flashes, increased sweating, sleep disturbance, increased nervous excitability, irritability, palpitations, cardialgia, dizziness, headache, decreased libido, muscle and joint pain); involution of the skin and mucous membranes, especially the mucous membranes of the genitourinary system (urinary incontinence, dryness and irritation of the vaginal mucosa, pain during sexual intercourse).

HRT with an adequate dose of estrogen, such as that found in Proginova, reduces bone resorption and delays or stops postmenopausal bone loss. Long-term use of hormone replacement therapy (HRT) has been shown to reduce the risk of peripheral bone fractures in postmenopausal women. When HRT is discontinued, the rate of bone mass decline is comparable to that characteristic of the period immediately after menopause. It has not been proven that using HRT can restore bone mass to premenopausal levels.

HRT also has a beneficial effect on the collagen content of the skin, as well as its density, and may also slow down the formation of wrinkles.

HRT leads to a decrease in total cholesterol, low-density lipoprotein (LDL) cholesterol and an increase in high-density lipoprotein (HDL) cholesterol, as well as an increase in triglyceride levels. The addition of a progestin may, to a certain extent, interfere with the effects of estradiol on metabolism. Overall, the metabolic effects of HRT are considered beneficial and are thought to be involved in reducing the risk of cardiovascular disease in postmenopausal women.

For women with a non-removed uterus, when using Progynova, additional administration of gestagen is recommended for at least 10 days in each cycle. This reduces the risk of developing endometrial hyperplasia and the concomitant risk of adenocarcinoma in women in this group.

Active ingredient

Estradiol valerate

Composition

1 tablet contains:

Active ingredient:

estradiol valerate 2 mg;

Excipients:

lactose monohydrate 46 – 250 mg;

corn starch 26 – 200 mg;

povidone 25000 – 3 mg;

talc – 2.4 mg;

magnesium stearate – 0.15 mg;

crystalline sucrose 33 – 540 mg;

povidone 700000 – 0.323 mg;

macrogol 6000 – 3.719 mg;

calcium carbonate precipitated 14 – 572 mg;

talc – 7.104 mg;

glycerol 85% (w/w) – 0.205 mg;

titanium dioxide (E171, C.1.77891) – 0.411 mg;

indigo carmine (E132, C.1.73015) – 0.051 mg;

montaglycol wax – 0.075 mg.

Contraindications

pregnancy;
lactation period;
bleeding from the vagina of unknown origin;
confirmed or suspected breast cancer;
confirmed or suspected hormone-dependent precancerous diseases or hormone-dependent malignant tumors;
liver tumors currently or in the past (benign or malignant);
severe liver disease;
acute arterial thrombosis or thromboembolism (such as myocardial infarction, stroke);
deep vein thrombosis in the acute stage, thromboembolism currently or in the past;
presence of a high risk of venous and arterial thrombosis;
severe hypertriglyceridemia;
congenital deficiency of lactase, sucrase/isomaltase, lactose intolerance, glucose-galactose malabsorption;
children and adolescents up to 18 years of age;
hypersensitivity to the components of the drug Proginova.

Side Effects

In rare cases – headache, nausea, stomach dysfunction, breast engorgement, changes in body weight, uterine bleeding, chloasma.

Storage conditions

At a temperature not exceeding 30 °C.

Shelf life

5 years

Manufacturer

Delpharm Lille S.a.S., France